Supériorité du sécukinumab sur l’ustékinumab dans le psoriasis en plaques modéré à sévère de l’adulte : résultats de l’étude CLEAR à 1 an
J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Diamant Thaçi(University of Lübeck), Kristian Reich(Dermatologikum Hamburg), P. Celérier(Centre Hospitalier de La Rochelle), Külli Kingo(Tartu University Hospital), M. Beylot‐Barry(Université de Bordeaux), Andreas Pinter(Goethe University Frankfurt), Michael Ziv(Emek Medical Center), Lucie Martin(Novartis (France)), M. Milutinovic(Novartis (Switzerland)), R. You(Novartis (China)), M. Ruer‐Mulard, Andrew Blauvelt(Veterans Health Administration), A. Khemis(Hôpital l'Archet), Sophie Hugot(Novartis (Switzerland)), Tsen-Fang Tsai(National Taiwan University Hospital), Ronald Vender(Dermatrials Research), A.S. Blanc(Novartis (France)), Stephen K. Tyring(Center for Clinical Studies)
Cited by 1
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
|Clinical Reviews in Allergy & Immunology|2018|738